Nonalcoholic Steatohepatitis

Elizabeth M. Brunt

doi:10.1055/s-2004-823098

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2004; 24(1): 3-20
DOI: 10.1055/s-2004-823098

Nonalcoholic Steatohepatitis

Elizabeth M. Brunt¹

¹Associate Professor of Pathology, Saint Louis University Liver Center, Saint Louis University Health Sciences Center, Department of Pathology, St. Louis, Missouri

Abstract

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined aggregate of disorders related to obesity, insulin resistance, type II diabetes, hypertension and hyperlipidemia. Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis. The diagnosis of nonalcoholic steatohepatitis requires histopathologic evaluation because the lesions of parenchymal injury and fibrosis cannot be detected by imaging studies or laboratory tests. This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis.

KEYWORDS

Nonalcoholic fatty liver disease - nonalcoholic steatohepatitis - obesity - metabolic syndrome - insulin resistance

Full Text

References

REFERENCES

1 Sanyal A J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123 1705-1725
2 Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003; 37 1202-1219
3 McCullough A J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002; 34 255-262
4 Dixon J B, O'Brien P E, Bhatal P S. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply). Gastroenterology. 2002; 122 841-842
5 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21 3-16
6 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55 434-438
7 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979; 67 811-816
8 Nasrallah S M, Wills C E, Galambos J T. Hepatic morphology in obesity. Dig Dis Sci. 1981; 26 325-327
9 Silverman J F, O'Brien K F, Long S et al.. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990; 85 1349-1355
10 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol. 1995; 104 23-31
11 Teli M R, James O FW, Burt A D, Bennett M K, Day C P. The natural history of nonalcoholic fatty liver-a follow-up study. Hepatology. 1995; 22 1714-1719
12 Falck-Ytter Y, Younossi Z M, Marchesini G, McCullough A J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001; 21 17-26
13 Matteoni C A, Younossi Z M, Gramlich T et al.. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116 1413-1419
14 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122 1649-1657
15 Clark J M, Diehl A M. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology. 2003; 124 248-250
16 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121 91-100
17 Wigg A J, Roberts-Thomson I C, Dymock R B et al.. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48 206-211
18 Farrell G C. Is bacterial ash the flash that ignites NASH?. Gut. 2001; 48 148-149
19 Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome-prevalence and determinants of a “bright” liver echopattern. Ital J Gastroenterol Hepatol. 1997; 29 351-356
20 Bellentani S, Sacciccio G, Masutti F et al.. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000; 132 112-117
21 Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol. 2001; 35 531-537
22 Saadeh S, Younossi Z M, Remer E M et al.. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123 745-750
23 Ruhl C E, Everhart J E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003; 124 71-79
24 Prati D, Taioli E, Zanella A et al.. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137 1-9
25 Expert panel on Detection . Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001; 285 2486-2497
26 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98 960-967
27 Kim W R, Brown R S, Terrault N A, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002; 36 227-242
28 Yu A S, Keefe E B. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? (editorial). Am J Gastroenterol. 2003; 98 955-956
29 Clinical Practice Committee AGA . AGA medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2003; 123 1364-1366
30 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37 1286-1292
31 Mulhall B P, Ong J P, Younossi Z M. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002; 17 1136-1143
32 Hilden M, Christoffersen P, Juhl E, Dalgaard J B. Liver histology in a “normal” population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol. 1977; 12 593-597
33 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12 1106-1110
34 Charlton M, Kasparova P, Weston S et al.. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001; 7 608-614
35 Youssef W I, McCullough A J. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 2002; 13 17-30
36 Marchesini G, Bugianesi E, Forlani G et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37 917-923
37 Roberts E A. Steatohepatitis in children. Best Pract Res Clin Gastroenterol. 2002; 16 749-765
38 Caldwell S H, Oelsner D H, Iezzoni J C et al.. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999; 29 664-669
39 Bacon B R, Farahvash M J, Janney C G, Neuschwandertetri B A. Nonalcoholic steatohepatitis-an expanded clinical entity. Gastroenterology. 1994; 107 1103-1109
40 Chitturi S, Farrell G C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21 27-41
41 Farrell G C. Drugs and steatohepatitis. Semin Liver Dis. 2002; 22 185-194
42 Garcia-Monzon C, Fernandez-Bermejo M. A wider view of diagnostic criteria of nonalcoholic steatohepatitis (letter to the editor). Gastroenterology. 2002; 122 840-841
43 Garcia-Monzon C, Martin-Perez E, Lo Iacono O et al.. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000; 33 716-724
44 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346 1221-1231
45 Neuschwander-Tetri B A. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2002; 4 31-36
46 Skelly M M, James P D, Ryder S D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001; 35 195-199
47 Marceau P, Biron S, Hould F S et al.. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999; 84 1513-1517
48 Cortez-Pinto H, Camilo M E, Baptista A, De Oliveira A G, De Moura M C. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr. 1999; 18 353-358
49 Marchesini G, Brizi M, Morselli-Labate A M et al.. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107 450-455
50 Marchesini G, Brizi M, Bianchi G et al.. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50 1844-1850
51 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002; 35 367-372
52 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35 373-379
53 Youssef W I, McCullough A J. Steatohepatitis in obese individuals (review). Best Pract Res Clin Gastroenterol. 2002; 16 733-747
54 Neuschwander-Tetri B A, Brunt E M, Wehmeier K R, Oliver D, Bacon B R. Improved nonalcoholic steatohepatitis following 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38 1008-1017
55 Neuschwander-Tetri B A, Brunt E M, Wehmeier K R et al.. Interim results of a pilot study demonstrating the early effects of the PPAR-g ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003; 38 434-440
56 Marchesini G, Brizi M, Bianchi G et al.. Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358 893-894
57 Caldwell S H, Hespenheide E E, Redick J A et al.. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001; 96 519-525
58 Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis. 2001; 21 57-69
59 Day C P, Saksena S. Nonalcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002; 17 S377-S384
60 Day C P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16 663-678
61 Lebovitz H E. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl. 2003; 134 18-27
62 Paradis V, Perlemuter G, Bonvoust F et al.. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001; 34 738-744
63 Leclercq I A, Farrell G C, Schriemer R, Robertson G R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002; 37 206-213
64 Angulo P, Lindor K D. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis. 2001; 21 81-88
65 Angulo P, Lindor K D. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16 797-810
66 O'Brien P E, Dixon J B. The extent of the problem of obesity. Am J Surg. 2002; 184 4S-8S
67 Korner J, Leibel R L. To eat or not to eat-how the gut talks to the brain. N Engl J Med. 2003; 349 926-928
68 McCullough A J, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology. 1999; 29 1328-1330
69 Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003; 14 137-145
70 Prins J B. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab. 2002; 16 639-651
71 Kern P A, Di Gregorio G B, Lu T, Rassouli N, Ranganathan G. Adiponectin exprssion from human adipose tissue. Relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes. 2003; 52 1779-1785
72 Stumvoll M. Thiazolidinediones-some recent developments. Expert Opin Investig Drugs. 2003; 12 1179-1187
73 Das U N. Is metabolic syndrome X an inflammatory condition? (Review). Exp Biol Med (Maywood). 2002; 227 989-997
74 Xu A, Wang Y, Keshaw H et al.. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112 91-100
75 Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003; 38 244-251
76 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997; 12 398-403
77 Lee R G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989; 20 594-598
78 Diehl A M, Goodman Z, Ishak K G. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988; 95 1056-1062
79 Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987; 82 650-654
80 Brunt E M. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis. 2002; 6 399-420
81 Brunt E M, Tiniakos D G. Pathology of steatohepatitis (review). Best Pract Res Clin Gastroenterol. 2002; 16 691-707
82 Burt A D, Mutton A, Day C P. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol. 1998; 15 246-258
83 Garg A, Misra A. Hepatic steatosis, insulin resistance and adipose tissue disorders (editorial). J Clin Endocrinol Metab. 2002; 87 3019-3022
84 Ishak K G. Light microscopic morphology of viral hepatitis. Am J Clin Pathol. 1976; 65 787-827
85 Natori S, Rust C, Stadheim L M et al.. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol. 2001; 34 248-253
86 Ziol M, Tepper M, Lohez M et al.. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol. 2001; 34 254-260
87 Canbay A, Tamir P, Torok N J et al.. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003; 83 655-663
88 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003; 125 437-443
89 Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis (letter to editor). Am J Gastroenterol. 1999; 94 3379
90 Dourakis S P, Sevastinaos V A, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy (letter to editor). Am J Gastroenterol. 2002; 97 1074-1075
91 Caldwell S H, Hespenheide E E. Subacute liver failure in obese women. Am J Gastroenterol. 2002; 97 2058-2062
92 Brunt E M, Ramrakhiani S, Cordes B G et al.. Concurrence of histologic features of steathepatitis with other forms of chronic liver disease. Mod Pathol. 2003; 16 49-56
93 Brunt E M, Tiniakos D G. Steatosis, steatohepatitis: review of effects on chronic hepatitis C. Current Hepatitis Reports. 2002; 1 38-44
94 Clouston A D, Powell E E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002; 16 767-781
95 Ong J P, Younossi Z M, Speer C et al.. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001; 21 266-271
96 Washington K, Wright K, Shyr Y et al.. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol. 2000; 31 822-828
97 Cortez-Pinto H, Baptista A, Camilo M E, de Moura M C. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterol. 2001; 48 87-90
98 Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol. 2000; 32 689-702
99 Ludwig J, McGill D B, Lindor K D. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997; 12 398-403
100 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94 2467-2474
101 Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H. Mallory body-a disease-associated type of sequestosome. Hepatology. 2002; 35 1053-1062
102 Savas M C, Koruk M, Pirim I et al.. Serum ubiquitin levels in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2003; 50 738-741
103 Teli M R, Day C P, Burt A D, Bennett M J, James O F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995; 346 987-990
104 Caldwell S H, Swerdlow R H, Khan E M et al.. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999; 31 430-434
105 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120 1183-1192
106 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998; 114 311-318
107 Younossi Z M, Gramlich T, Bacon B R et al.. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 1999; 30 847-850
108 Bonkovsky H L, Jawaid Q, Tortorelli K et al.. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999; 31 421-429
109 Chitturi S, Weltman M, Farrell G C et al.. HFE Mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 2002; 36 142-149
110 Cortez-Pinto H, Baptista A, Camilo M E et al.. Nonalcoholic steatohepatitis-clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996; 41 172-179
111 Abdelmalek M, Angulo P, Jorgensen R A, Sylvestre P B, Lindor K. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001; 96 2711-2717
112 Laurin J, Lindor K D, Crippin J S et al.. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis-a pilot study. Hepatology. 1996; 23 1464-1467
113 Andersen T, Gluud C, Franzmann M-B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12 224-229
114 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30 1356-1362
115 Ratziu V, Giral P, Charlotte F et al.. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118 1117-1123
116 Dixon J B, Bhatal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121 91-100
117 Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res. 2002; 24 429-438
118 Evans C DJ, Oien K A, MacSween R NM, Mills P R. Nonalcoholic steatohepatitis: a common cause of advanced liver injury?. J Clin Pathol. 2002; 55 689-692
119 Brunt E M. Grading and staging the histopathologcial lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000; 31 241-246
120 Abdelmalek M, Ludwig J, Lindor K D. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol. 1995; 20 127-130
121 Contos M J, Cales W, Sterling R K et al.. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7 363-373
122 Shimada M, Hashimoto E, Taniai M et al.. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002; 37 154-160
123 Hui J M, Kench J G, Chitturi S et al.. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38 420-427
124 Calle E E, Rodriguez C, Walker-Thurmond K, Thun M J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348 1625-1638
125 Nair S, Mason A, Eason J, Loss G, Perillo R P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology. 2002; 36 150-155
126 Marrero J A, Fontana R J, Su G L et al.. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002; 36 1349-1354
127 Ratziu V, Bonyhay L, Di Martino V et al.. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002; 35 1485-1493
128 Balkau B, Kahn H S, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. Diabetes Care. 2001; 24 843-849
129 Yang S, Lin H Z, Hwang J, Chacko V P, Diehl A M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Res. 2001; 61 5016-5023

Elizabeth M BruntM.D.

4th Floor FDT, Saint Louis University Hospital

3635 Vista Avenue at Grand Boulevard

St. Louis, MO 63110

Email: bruntem@slu.edu